Nieuwenhuys Angela, Papageorgiou Eirini, Pataky Todd, De Laet Tinne, Molenaers Guy, Desloovere Kaat
Department of Rehabilitation Sciences, KU Leuven, Leuven, Belgium.
Clinical Motion Analysis Laboratory, University Hospitals Leuven, Leuven, Belgium.
PLoS One. 2016 Mar 31;11(3):e0152697. doi: 10.1371/journal.pone.0152697. eCollection 2016.
This study aimed at comparing two statistical approaches to analyze the effect of Botulinum Toxin A (BTX-A) treatment on gait in children with a diagnosis of spastic cerebral palsy (CP), based on three-dimensional gait analysis (3DGA) data. Through a literature review, the available expert knowledge on gait changes after BTX-A treatment in children with CP is summarized.
Part 1--Intervention studies on BTX-A treatment in children with CP between 4-18 years that used 3DGA data as an outcome measure and were written in English, were identified through a broad systematic literature search. Reported kinematic and kinetic gait features were extracted from the identified studies. Part 2--A retrospective sample of 53 children with CP (6.1 ± 2.3years, GMFCS I-III) received 3DGA before and after multilevel BTX-A injections. The effect of BTX-A on gait was interpreted by comparing the results of paired samples t-tests on the kinematic gait features that were identified from literature to the results of statistical parametric mapping analysis on the kinematic waveforms of the lower limb joints.
Part 1-53 kinematic and 33 kinetic features were described in literature. Overall, there is no consensus on which features should be evaluated after BTX-A treatment as 49 features were reported only once or twice. Part 2--Post-BTX-A, both statistical approaches found increased ankle dorsiflexion throughout the gait cycle. Statistical parametric mapping analyses additionally found increased knee extension during terminal stance. In turn, feature analyses found increased outtoeing during stance after BTX-A.
This study confirms that BTX-A injections are a valuable treatment option to improve gait function in children with CP. However, different statistical approaches may lead to different interpretations of treatment outcome. We suggest that a clear, definite hypothesis should be stated a priori and a commensurate statistical approach should accompany this hypothesis.
本研究旨在基于三维步态分析(3DGA)数据,比较两种统计方法来分析A型肉毒杆菌毒素(BTX-A)治疗对痉挛型脑性瘫痪(CP)儿童步态的影响。通过文献综述,总结了关于CP儿童接受BTX-A治疗后步态变化的现有专家知识。
第1部分——通过广泛的系统文献检索,确定了4至18岁CP儿童接受BTX-A治疗的干预研究,这些研究将3DGA数据作为结局指标且以英文撰写。从已确定的研究中提取报告的运动学和动力学步态特征。第2部分——对53例CP儿童(6.1±2.3岁,GMFCS I-III级)进行回顾性抽样,在多级BTX-A注射前后接受3DGA检查。通过比较配对样本t检验对从文献中确定的运动学步态特征的结果与下肢关节运动学波形的统计参数映射分析结果,来解释BTX-A对步态的影响。
第1部分——文献中描述了53个运动学特征和33个动力学特征。总体而言,对于BTX-A治疗后应评估哪些特征尚无共识,因为49个特征仅被报告了一两次。第2部分——BTX-A治疗后,两种统计方法均发现整个步态周期中踝关节背屈增加。统计参数映射分析还发现终末站立期膝关节伸展增加。反过来,特征分析发现BTX-A治疗后站立期外翻增加。
本研究证实BTX-A注射是改善CP儿童步态功能的一种有价值的治疗选择。然而,不同的统计方法可能导致对治疗结果的不同解释。我们建议应事先明确陈述清晰、明确的假设,并应伴随与该假设相称的统计方法。